Hearing of the House Foreign Affairs Committee, Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations, And Subcommittee on the Western Hemisphere

Research Conducted and Supported by the National Institutes of Health in Addressing Zika Virus Disease


Anthony S. Fauci, M.D.
Director
National Institute of Allergy
and Infectious Diseases
National Institutes of Health
February 10, 2016





NIAID Research: A Dual Mandate

Maintain and "grow" a robust basic and applied research portfolio in microbiology, infectious diseases, immunology and immune-mediated diseases



Respond rapidly to new and emerging disease threats


New/Improved Interventions



published online January 13, 2016

Zika Virus in the Americas — Yet Another Arbovirus Threat

AS Fauci and DM Morens



Research





Resources for Researchers/ Industry to Advance Product Development

Biomedical Research Response: Epidemiology and Natural History

- Epidemiology and natural history
 - Symptomatic vs. asymptomatic
 - Frequency of sequelae

Pathogenesis of microcephaly

Biomedical Research Response: Basic Science

Molecular Virology: a) elucidate viral structure;
 b) compare viruses from different outbreaks

Pathogenesis of disease

Studies on immune response (innate and adaptive)

Establish animal models

Biomedical Research Response: Vector Control

Vector competence: Ability of mosquitoes other than Aedes aegypti to carry and transmit Zika virus

Novel insecticides

Novel vector control methods

Biomedical Research Response: Diagnostics


- CDC Diagnostic and Reference Laboratory in Arbovirus Diseases Branch
- RT-PCR assay for Zika, Dengue and Chikungunya
- Antibody assay for acute infection that will not cross-react with other flaviviruses

Biomedical Research Response: Countermeasures – Vaccines

DNA vaccine – success with West Nile Virus

Live-attenuated vaccine (for non-obstetric population) – success with dengue

DNA Vaccine Approach



Biomedical Research Response: Countermeasures – Therapeutics

- Developed in vitro antiviral screening assay
- Testing compounds with known activity against other flaviviruses
- Broad screening of compounds without known anti-flavivirus activity
- "Targeted" antiviral approach similar to HIV and Hepatitis C

Volume 8, Issue 11 November 2008

THE LANCET Infectious Diseases

Emerging Infections: A Perpetual Challenge

DM Morens, GK Folkers & AS Fauci

